Herceptin, Enbrel Face First Biosimilar Rivals In Japan But Outlook Uncertain
The first biosimilar versions in Japan of two major biologic therapies, Herceptin and Enbrel, have been awarded reimbursement prices, clearing the way for launch, but commercial prospects remain uncertain.
You may also be interested in...
China’s Everest licenses global rights to Novartis FGFR4 inhibitor, while Altogen and Lynkogen partner in NASH and metabolic disease.
It was another busy year for Japanese regulators, who approved 38 new drugs in the fiscal year up to the end of this March, roughly maintaining the pace of the the previous 12 months and bringing some important new therapies to patients. New products for oncology and biologics featured heavily, with foreign multinationals dominating the list.
Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key new products reach the global market and others begin to face generic competition. In this second and final part of an exclusive interview with Scrip, he talks about major mid-term growth prospects, recent pricing reforms in Japan, and how Chugai is tapping into novel disruptive technologies.